However, several studies have revealed that low levels of IGFBP1 are related to increased risk of tumor progression and significant poor survival in breast cancer [16], colorectal cancer [17], and hepatocellular carcinoma [13]. This evidence concerns the gene IGFBP1 and hepatocellular carcinoma.